HF-158K1 by HighField Biopharmaceuticals for Cervical Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Cervical Cancer.

BioMarin lays off 225 employees as it cuts spending on gene therapy rollout

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 30, 2024

Novo Nordisk acquires Embark and metabolic programme

The companies will develop new therapies for obesity and its related co-morbidities. Credit: abolukbas/Shutterstock.com. Novo Nordisk has acquired Embark Biotech and its lead asset targeting

August 31, 2023

Empatica aims to develop seizure-forecasting algorithm based on wearable data

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Empatica is preparing to run

December 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.